Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of August 2024, specifically dated August 30, 2024. The Company is a foreign private issuer based in Ramat Gan, Israel, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on a corporate financing transaction.
- Proposed Capital Raise: Up to $9.0 million in aggregate offering price.
- Security Type: American Depositary Shares (ADSs), each representing 300 ordinary shares.
- Transaction Costs: A fixed commission rate of 3.0% of the gross sales price payable to the sales agent.
Material Changes
On August 30, 2024, the Company entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. This agreement authorizes the Company to sell ADSs through an "at-the-market" offering program. The sales will be conducted pursuant to a shelf registration statement on Form F-3 (File No. 333-274316) declared effective in September 2023.
Outlook, Risks, and Management Commentary
Offering Mechanics: Sales may be made directly on or through The Nasdaq Capital Market, to market makers, or directly to the sales agent as principal. The sales agent will use commercially reasonable efforts to sell the ADSs based on instructions from the Company, including price or size limits.
Termination: The offering will terminate upon the earliest of the termination of the agreement by either party or mutual agreement.
Risks and Contingencies: The filing notes that the report does not constitute an offer to sell securities in any state where such an offer would be unlawful prior to registration. The description of the agreement is qualified by reference to the full text filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the current market price of Can-Fite ADSs to assess potential dilution from the $9.0 million offering.
- Review the full text of the At The Market Offering Agreement (Exhibit 10.1) for specific conditions and termination rights.
- Confirm the Company's current cash position and burn rate to understand the necessity of this capital raise.
- Check for any subsequent filings indicating the actual volume of shares sold under this agreement since August 30, 2024.